Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.
Sirarat SarntivijaiShelley ZhangDesikan G JagannathanShadia ZamanKeith K BurkhartGilbert S OmennYongqun HeBrian D AtheyDarrell R AbernethyPublished in: Drug safety (2017)
By expanding the existing OAE ontological design, our TKI use case demonstrated that the combination of OAE and MedDRA(®) provides a semantic framework to link clinical phenotypes of adverse drug events to biological mechanisms.